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Long-Term Prognostic Implications of Cerebral Microbleeds in
Chinese Patients With Ischemic Stroke
Kui Kai Lau, MRCP; Yuen Kwun Wong, MSc; Kay Cheong Teo, MRCP; Richard S. K. Chang, MRCP; Man Yu Tse, MRCP; Chu Peng Hoi, MD;
Chung Yan Chan, MBBS; Oi Ling Chan, MBBS; Ryan Hoi Kit Cheung; Edmund Ka Ming Wong, MBBS; Joseph Shiu Kwong Kwan, MD; Edward
S. Hui, PhD; Henry Ka Fung Mak, MD, FRCR
Background-—This study was performed to determine the clinical correlates and long-term prognostic implications of microbleed
burden and location in Chinese patients with ischemic stroke.
Methods and Results-—We recruited 1003 predominantly Chinese patients with ischemic stroke who received magnetic
resonance imaging at the University of Hong Kong. We determined the clinical correlates of microbleeds and the long-term risks
(3126 patient-years of follow-up) of recurrent ischemic stroke and intracerebral hemorrhage (ICH) by microbleed burden (0 versus
1, 2–4, and ≥5) and location, adjusting for age, sex, and vascular risk factors and stratiﬁed by antithrombotic use. Microbleeds
were present in 450 of 1003 of the study population (119/450 had ≥5, 187/450 had mixed location). Having ≥5 microbleeds was
independently associated with prior antiplatelet and anticoagulant use, whereas microbleeds of mixed location were independently
associated with hypertension and prior anticoagulant use (all P<0.05). Microbleed burden was associated with an increased risk of
ICH (microbleed burden versus no microbleeds: 1 microbleed: multivariate hazard ratio: 0.59 [95% conﬁdence interval, 0.07–5.05];
2–4 microbleeds: multivariate hazard ratio: 2.14 [95% conﬁdence interval, 0.50–9.12]; ≥5 microbleeds: multivariate hazard ratio:
9.51 [95% conﬁdence interval, 3.25–27.81]; Ptrend<0.0001), but the relationship of microbleed burden and risk of recurrent
ischemic stroke was not signiﬁcant (Ptrend=0.054). Similar ﬁndings were noted in the 862 of 1003 patients treated with antiplatelet
agents only (ICH: Ptrend<0.0001; ischemic stroke Ptrend=0.096). Multivariate analysis revealed that, independent of vascular risk
factors, antithrombotic use, and other neuroimaging markers of small vessel disease, having ≥5 microbleeds (multivariate hazard
ratio: 6.08 [95% conﬁdence interval, 1.11–33.21]; P=0.037) was identiﬁed as an independent predictor of subsequent ICH, but
neither microbleed burden nor location was predictive of recurrent ischemic stroke risk.
Conclusions-—In Chinese patients with ischemic stroke, a high burden of cerebral microbleeds was signiﬁcantly associated with an
increased risk of ICH; however, neither microbleed location nor burden was associated with recurrent ischemic stroke risk. ( J Am
Heart Assoc. 2017;6:e007360. DOI: 10.1161/JAHA.117.007360.)
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C erebral microbleeds are markers of underlying smallvessel disease (SVD) burden.1 They may be due to
extravasation of red blood cells as a result of small vessel
rupture or blood–brain barrier dysfunction (most commonly
caused by hypertensive or cerebral amyloid angiopathy) but
also may be secondary to an ischemic insult.2,3
Recent systematic reviews have demonstrated that the risk
of recurrent ischemic stroke and intracerebral hemorrhage
(ICH) increases with microbleed burden and that the risk of
ICH increases more steeply than that of recurrent ischemic
stroke.4 Studies included in this systematic review, however,
were small in sample size or had a short duration of follow-up
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(15 studies with 9500 patient-years of follow-up).4 The
majority of these studies did not stratify results by antithrom-
botic use,4 potentially resulting in heterogeneity. Furthermore,
signiﬁcant ethnic differences in microbleed location exist.4
Asians with transient ischemic attack or ischemic stroke have
a high prevalence of microbleeds of mixed location (8–40%
versus 5–15% in white cohorts), whereas white patients with
transient ischemic attack or ischemic stroke have a high
prevalence of strictly lobar microbleeds (29–58% versus
6–27% in Asian cohorts), suggesting potential ethnic differ-
ences in underlying SVD etiology.4 It appears that patients
with microbleeds of mixed location have the highest risk of
recurrent ischemic stroke or ICH,4 but the underlying risk
factors leading to this particularly severe subgroup of SVD
remains uncertain. Finally, although recent small studies have
shown that susceptibility-weighted imaging has superior
reliability and sensitivity for microbleed detection compared
with T2* gradient echo,5,6 studies using susceptibility-
weighted imaging in determining the prevalence and prog-
nostic implications of microbleeds are scarce.4
We recently validated the prognostic value of the total SVD
score and studied the prognostic implications of the individual
components of the score, including microbleeds, in a large
cohort of predominantly Chinese patients with ischemic
stroke.7 Because cerebral microbleeds are important predic-
tors of subsequent ICH, we provide further details about the
clinical and imaging correlates of microbleed burden and
location and their long-term prognostic outcomes, stratiﬁed
by antithrombotic use, in a large cohort of 1003 predomi-
nantly Chinese patients with ischemic stroke (3100 patient-
years of follow-up), using susceptibility-weighted imaging.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
We prospectively studied 1076 predominantly Chinese
patients with a diagnosis of acute ischemic stroke who received
a magnetic resonance imaging (MRI) scan incorporating a
hemosiderin-sensitive sequence at the University of Hong Kong
MRI unit from March 1, 2008, to September 30, 2014.7,8
All patients gave written informed consent, or assent was
obtained from relatives of patients who were unable to
provide consent. The study was approved by the local
research ethics committee.
We collected demographic data, atherosclerotic risk fac-
tors, premorbid antithrombotic use, details of hospitalization
for the index event, and medications on discharge during face-
to-face interviews and cross-referenced these with primary
care and hospital records. Cause of ischemic stroke was
classiﬁed according to the modiﬁed TOAST (Trial of Org
10172 in Acute Stroke Treatment) criteria.9 Ischemic stroke
subtype was classiﬁed according to functional outcome,
which was estimated by calculating the modiﬁed Rankin Scale
on discharge.
All patients were scanned using a 3-T MRI scanner (Achieva;
Philips Healthcare), and microbleeds were detected using
susceptibility-weighted imaging. Details of scan parameters
were provided in our previous publications.7,8 A senior
neuroradiologist (H.K.F.M.) supervised the interpretation of
the MRI scans. Microbleeds were deﬁned as rounded,
hypodense foci up to 10 mm in size and were differentiated
from microbleed mimics.10 The locations and numbers of
microbleeds were scored according to the Microbleed
Anatomical Rating Scale,11 and microbleed burden was graded
as 0, 1, 2 to 4, and ≥5, as per recent systematic reviews.4 The
severity of white matter hyperintensity (WMH) was determined
according to the Fazekas scale.12 Subcortical WMH was
graded as 0 (absent), 1 (puntate foci), 2 (beginning conﬂuence
of foci), and 3 (large conﬂuent areas). Periventricular WMH was
graded as 0 (no WMH except for small triangular foci
surrounding the frontal horns), 1 (periventricular WMH
surrounding the anterior and posterior horns with or without
Clinical Perspective
What Is New?
• In a large cohort of Chinese patients with ischemic stroke,
we demonstrated that a high burden (≥5) of cerebral
microbleeds is independently associated with an increased
risk of intracerebral hemorrhage on long-term follow-up.
• Neither microbleed burden nor location was associated with
risk of recurrent ischemic stroke after adjusting for
confounding factors.
• In ischemic stroke patients on antiplatelet agents, the 5-
year absolute risk of recurrent ischemic stroke outweighs
that of intracerebral hemorrhage in patients with <5
cerebral microbleeds.
• In patients with ≥5 cerebral microbleeds, the 5-year
absolute risk of intracerebral hemorrhage approached that
of recurrent ischemic stroke.
What Are the Clinical Implications?
• Our ﬁndings suggest that in ischemic stroke patients,
presence of cerebral microbleeds should not be considered
a contraindication to antiplatelet agents if there are <5, as
the risk of recurrent ischemic stroke outweighs the risk of
intracerebral hemorrhage in this group of patients.
• In patients with ≥5 cerebral microbleeds, the long-term risk
of intracerebral hemorrhage is similar to that of recurrent
ischemic stroke; therefore, the potential risks and beneﬁts
of antiplatelet agents in this group of patients would need to
be carefully balanced.
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discrete WMHs), 2 (extensive patchy WMHs and their early
conﬂuent stages), and 3 (conﬂuent, completely surrounding
lateral ventricles). Basal ganglia (BG) and centrum semiovale
perivascular spaces were deﬁned as small (<3 mm) punctate
(if perpendicular to the plane of scan) or linear (if longitudinal
to the plane of scan) hyperintensities on T2 images in the BG
or centrum semiovale based on a previously validated scale.13
Lacunes were deﬁned as rounded or ovoid lesions; >3 and
<20 mm in diameter; in the BG, internal capsule, centrum
semiovale, or brainstem; of cerebrospinal ﬂuid signal density
on T2 and FLAIR; and with no increased signal on diffusion-
weighted imaging.14 The intrarater j for interpretation of
microbleed burden (0, 1, 2–4, and ≥5) in 50 randomly selected
scans was 0.81, and the interrater j was 0.84.
As part of routine clinical care, recruited patients were
followed up by a clinician every 3 to 6 months or more
frequently if indicated. All patients were assessed for the
following clinical outcomes: (1) recurrent stroke (ischemic and
hemorrhagic) and (2) mortality. The deﬁnition of recurrent
stroke required a sudden new neurological deﬁcit ﬁtting the
deﬁnition of ischemic stroke or ICH, occurring after a period
of unequivocal neurological stability and not attributable to
cerebral edema, mass effect, or hemorrhagic transformation
of the incident cerebral infarction. Patients with suspected
recurrent stroke received repeated neuroimaging in the form
of cranial computed tomography or MRI to support the
diagnosis. Vascular death was deﬁned as death due to lethal
cardiac arrhythmias, acute coronary syndrome, congestive
heart failure, fatal stroke, pulmonary embolism, aortic
dissection, or unexplained sudden death. If needed, details
of clinical outcomes were supplemented by electronic or
paper medical records from individual primary care practices,
hospitals, and the Deaths General Register Ofﬁce.
Statistical Analyses
We determined the clinical predictors of a high (≥5) microb-
leed burden and of microbleeds of mixed location by
determining relationships with age, male sex, vascular risk
factors (hypertension, hyperlipidemia, diabetes mellitus,
smoking, atrial ﬁbrillation), renal impairment (deﬁned as a
glomerular ﬁltration rate <60 mL/min per 1.73 m2, according
Table 1. Clinical and Imaging Characteristics of the Study
Population
Baseline Clinical Characteristics (N=1003) Results
Age, y, mean (SD) 69 (12)
Male (%) 601 (60)
Hypertension (%) 657 (66)
Diabetes mellitus (%) 284 (28)
Hyperlipidemia (%) 256 (26)
Ever smokers (%) 297 (30)
Atrial fibrillation (%) 130 (13)
Prior antiplatelet use (%) 218 (22)
Prior warfarin use (%) 20 (2)
Prior NOAC use (%) 3 (0.3)
Imaging characteristics
Delay of scan from assessment, d, median (IQR) 4 (3–6)
Patients with microbleeds, n (%) 450 (45)
Patients with 1 microbleed, n (%) 184 (18)
Patients with 2–4 microbleeds (%) 147 (15)
Patients with ≥5 microbleeds (%) 119 (12)
Patients with strictly deep microbleeds (%) 61 (6)
Patients with strictly lobar microbleeds (%) 161 (16)
Patients with strictly infratentorial microbleeds (%) 41 (4)
Patients with microbleeds of mixed location (%) 187 (19)
Patients with Fazekas grade 3 subcortical WMH (%) 155 (15)
Patients with Fazekas grade 3 periventricular WMH (%) 30 (3)
Patients with >20 basal ganglia PVSs* (%) 69 (7)
Patients with >20 centrum semiovale PVSs* (%) 101 (10)
Patients with lacunes* 430 (44)
Postevent antithrombotic use
Antiplatelets only
Single antiplatelet, n (%) 725 (72)
Dual antiplatelet, n (%) 137 (14)
Anticoagulants only
Warfarin, n (%) 50 (5)
NOAC, n (%) 35 (3)
Combined anticoagulant and antiplatelet, n (%) 19 (2)
Not on antithrombotic agents, n (%) 37 (4)
Outcome
Follow-up time, mo, mean 3720
Patient-years of follow-up 3126
Recurrent stroke, n (%) 113 (11)
Ischemic, n (%) 93 (9)
Fatal, n (%) 13 (14)
Intracerebral hemorrhage, n (%) 20 (2)
Continued
Table 1. Continued
Baseline Clinical Characteristics (N=1003) Results
Fatal, n (%) 6 (30)
Death, n (%) 130 (13)
Vascular death, n (%) 60 (46)
IQR indicates interquartile range; NOAC, non–vitamin K antagonist oral anticoagulant;
PVS, perivascular space; WMH, white matter hyperintensity.
*Data missing for 29 patients.
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to the Chronic Kidney Disease Epidemiology Collaboration
equation for Asian populations15), and premorbid use of
antiplatelet agents or anticoagulants, as well as other
neuroimaging markers of SVD (subcortical and periventricular
WMH, BG and centrum semiovale perivascular spaces,
lacunes). Logistic regression was used in a univariate model
Table 2. Clinical Correlates of a High Burden (≥5) of Cerebral Microbleeds*
Univariate OR
(95% CI) P Value
Age- and Sex-Adjusted
OR (95% CI) P Value
Multivariate†
Adjusted OR (95% CI) P Value
Age 1.01 (1.00–1.03) 0.096 1.02 (1.00–1.03) 0.066 0.98 (0.96–1.00) 0.090
Male sex 1.26 (0.85–1.88) 0.26 1.33 (0.89–1.99) 0.17 1.28 (0.78–2.11) 0.33
Hypertension 1.65 (1.07–2.55) 0.024 1.57 (1.01–2.44) 0.047 1.66 (0.98–2.79) 0.057
Diabetes mellitus 0.88 (0.57–1.36) 0.56 0.85 (0.55–1.32) 0.47 0.77 (0.46–1.28) 0.31
Hyperlipidemia 0.93 (0.60–1.46) 0.76 0.96 (0.61–1.49) 0.84 0.79 (0.47–1.34) 0.38
Ever smoker 1.04 (0.68–1.57) 0.87 0.94 (0.60–1.49) 0.79 1.07 (0.64–1.79) 0.79
Atrial fibrillation 0.96 (0.54–1.72) 0.90 0.86 (0.47–1.55) 0.61 0.56 (0.26–1.24) 0.15
GFR <60 mL/min/1.73 m2 1.95 (1.28–2.98) 0.002 1.84 (1.18–2.87) 0.007 1.54 (0.92–2.59) 0.10
Premorbid antiplatelet use 1.38 (0.89–2.14) 0.15 1.29 (0.83–2.02) 0.26 2.01 (1.17–3.47) 0.012
Premorbid anticoagulant use 2.11 (0.77–5.79) 0.15 2.01 (0.73–5.54) 0.18 4.47 (1.17–17.10) 0.029
Fazekas grade 3 subcortical WMH 4.69 (3.09–7.13) <0.0001 3.41 (2.33–4.99) <0.0001 3.62 (2.24–5.85) <0.0001
Fazekas grade 3 periventricular WMH 9.65 (4.58–20.35) <0.0001 6.62 (3.09–14.17) <0.0001 8.63 (3.58–20.84) <0.0001
>20 Basal ganglia PVSs 7.79 (4.61–13.15) <0.0001 4.33 (2.57–7.28) <0.0001 6.07 (3.25–11.34) <0.0001
>20 Centrum semiovale PVSs 0.89 (0.46–1.71) 0.72 1.43 (0.88–2.33) 0.15 0.72 (0.35–1.50) 0.38
Lacunes 1.28 (0.87–1.89) 0.21 1.36 (0.99–1.89) 0.062 1.25 (0.80–1.94) 0.33
CI indicates conﬁdence interval; GFR, glomerular ﬁltration rate; OR, odds ratio; PVS, perivascular space; WMH, white matter hyperintensity.
*Compared with <5 microbleeds as reference.
†Age, sex, hypertension, hyperlipidemia, diabetes mellitus, atrial ﬁbrillation, smoking history, GFR <60 mL/min/1.73 m2, and all neuroimaging markers of small vessel disease.
Table 3. Clinical Characteristics of Patients With No, Strictly Deep, and Strictly Lobar Microbleeds and Microbleeds of Mixed
Location
No Microbleeds
(n=553)
Strictly Deep
Microbleeds
(n=61)
Strictly Lobar
Microbleeds
(n=161)
Microbleeds of
Mixed Location
(n=187) P Value
Age, y (SD) 68 (12) 68 (13) 70 (12) 72 (12) 0.001
Male sex 321 (58) 37 (61) 92 (57) 123 (66) 0.27
Hypertension 340 (62) 38 (62) 112 (70) 140 (75) 0.005
Diabetes mellitus 152 (28) 14 (23) 50 (31) 52 (28) 0.66
Hyperlipidemia 138 (25) 11 (18) 47 (29) 48 (26) 0.39
Ever smoker 155 (28) 16 (26) 53 (33) 60 (32) 0.50
Atrial fibrillation 79 (14) 7 (12) 17 (11) 24 (13) 0.63
GFR <60 mL/min/1.73 m2 102 (19) 8 (13) 39 (25) 56 (30) 0.002
Premorbid antiplatelet use 118 (21) 14 (23) 34 (21) 45 (24) 0.87
Premorbid anticoagulant use 12 (2) 0 (0) 2 (1) 8 (4) 0.14
Fazekas grade 3 subcortical WMH 58 (11) 11 (18) 20 (12) 60 (32) <0.0001
Fazekas grade 3 periventricular WMH 8 (1) 2 (3) 1 (1) 18 (10) <0.0001
>20 basal ganglia PVSs 20 (4) 4 (7) 8 (5) 35 (19) <0.0001
>20 centrum semiovale PVSs 43 (8) 9 (15) 18 (11) 25 (13) 0.087
Lacunes 221 (42) 33 (55) 65 (41) 94 (51) 0.046
Data are shown as count (percentage) unless otherwise noted. GFR indicates glomerular ﬁltration rate; PVS, periventricular space; WMH, white matter hyperintensity.
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adjusted for age and sex and in a multivariate adjusted model,
adjusted for all variables. A cutoff of ≥5 was used because
having ≥5 microbleeds has been shown in recent systematic
reviews to be associated with a steep rise in ICH risk
compared with <5 microbleeds.4
We used Kaplan–Meier survival analysis to calculate the 5-
year risk of recurrent ischemic stroke and ICH among all
patients, censored at death or March 31, 2015. Risks of
adverse events by microbleed burden and microbleed location
were compared with the log-rank test. We also used
competing-risks regression16 to estimate the subdistribution
hazard ratios (SHRs) for development of a recurrent ischemic
stroke and ICH in patients with presence of microbleeds and
with 1, 2 to 4, and ≥5 microbleeds, compared with those with
no microbleeds as a reference. Death was treated as a
competing risk event in the analysis of recurrent ischemic
stroke and ICH, whereas noncardiovascular death was treated
as a competing risk event for vascular death. Three models
were used: (1) an unadjusted model, (2) a model adjusted for
age and sex, and (3) a model adjusted for age, sex, and
vascular risk factors known to be associated with stroke and
death, including hypertension, hyperlipidemia, diabetes mel-
litus, smoking history, and atrial ﬁbrillation. We stratiﬁed our
analysis by antithrombotic use by performing subgroup
analyses of 862 antiplatelet users (anticoagulant users
excluded), 50 patients on warfarin, and 35 patients on non–
vitamin K antagonist oral anticoagulants (antiplatelet users
excluded) on discharge.
Finally, we determined the independent predictors of
recurrent ischemic stroke and ICH in a competing-risks
multivariate adjusted regression model by incorporating age,
sex, all vascular risk factors, antiplatelet and warfarin use,
microbleed burden and location (strictly deep, strictly lobar,
and strictly infratentorial), and other neuroimaging markers of
SVD into the model.
All analyses were done with SPSS version 22 (IBM Corp)
and STATA version 14.0 (StataCorp).
Results
A total of 1076 patients with ischemic stroke received an MRI
stroke protocol at the University of Hong Kong MRI unit during
the period from March 1, 2008, to September 30, 2014. In
total, 73 patients (6.8%) had incomplete clinical or imaging
data or were lost to follow-up and were excluded from the
ﬁnal analysis. These patients did not differ in terms of mean
age, sex, or prevalence and burden of microbleeds compared
with the 1003 patients included in the main analysis (all
P>0.05). Clinical and neuroimaging characteristics of the
study population are shown in Table 1. The mean age of the
study population was 69 years, and 60% were men. Overall,
66% had a past history of hypertension. In addition, 45%
(450/1003) had presence of microbleeds, of which 26%
(119/450) had ≥5 microbleeds and 42% (187/450) had
microbleeds of mixed location. Furthermore, 36% (161/450)
and 14% (61/450) of patients with microbleeds were strictly
Table 4. Clinical Correlates of Cerebral Microbleeds of Mixed Location
Unadjusted OR
(95% CI) P Value
Age- and Sex-Adjusted
OR (95% CI) P Value
Multivariate* Adjusted
OR (95% CI) P Value
Age 1.03 (1.01–1.04) 0.0002 1.03 (1.02–1.04) <0.0001 1.01 (1.00–1.03) 0.13
Male sex 1.36 (0.97–1.90) 0.071 1.51 (1.07–2.12) 0.018 1.50 (1.00–2.25) 0.052
Hypertension 1.72 (1.20–2.47) 0.003 1.55 (1.08–2.24) 0.019 1.58 (1.05–2.39) 0.029
Diabetes mellitus 0.97 (0.68–1.38) 0.86 0.92 (0.64–1.31) 0.64 0.81 (0.54–1.21) 0.29
Hyperlipidemia 1.01 (0.70–1.45) 0.96 1.05 (0.73–1.52) 0.80 0.96 (0.64–1.45) 0.85
Ever smoker 1.15 (0.82–1.63) 0.41 1.05 (0.71–1.53) 0.82 1.16 (0.77–1.74) 0.48
Atrial fibrillation 0.99 (0.61–1.59) 0.95 0.79 (0.48–1.29) 0.35 0.56 (0.30–1.05) 0.070
GFR <60 mL/min/1.73 m2 1.83 (1.28–2.62) 0.001 1.52 (1.04–2.21) 0.030 1.34 (0.88–2.05) 0.17
Premorbid antiplatelet use 1.18 (0.82–1.71) 0.39 1.02 (0.70–1.50) 0.91 1.31 (0.84–2.03) 0.24
Premorbid anticoagulant use 2.39 (1.00–5.72) 0.051 2.19 (0.91–5.30) 0.081 4.33 (1.42–13.25) 0.010
Fazekas grade 3 subcortical WMH 3.59 (2.47–5.21) <0.0001 3.41 (2.33–4.99) <0.0001 2.56 (1.70–3.87) <0.0001
Fazekas grade 3 periventricular WMH 7.14 (3.37–15.09) <0.0001 6.62 (3.09–14.17) <0.0001 5.68 (2.49–12.97) <0.0001
>20 basal ganglia PVSs 5.15 (3.12–8.53) <0.0001 4.33 (2.57–7.28) <0.0001 3.35 (1.90–5.90) <0.0001
>20 centrum semiovale PVSs 1.46 (0.90–2.37) 0.13 1.43 (0.88–2.33) 0.15 1.33 (0.79–2.25) 0.28
Lacunes 1.37 (1.00–1.89) 0.052 1.36 (0.99–1.89) 0.062 1.29 (0.91–1.84) 0.16
CI indicates conﬁdence interval; GFR indicates glomerular ﬁltration rate; OR, odds ratio; PVS, periventricular space; WMH, white matter hyperintensity.
*Age, sex, hypertension, hyperlipidemia, diabetes mellitus, atrial ﬁbrillation, smoking, GFR <60 mL/min/1.73 m2, and all neuroimaging markers of small vessel disease.
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lobar and strictly deep, respectively, in location. In total, 425
of 1003 (42%) patients were classiﬁed as having an ischemic
stroke due to small vessel occlusion, 342 of 1003 (34%) had
ischemic stroke due to large artery atherosclerosis, and 124
of 1003 (12%) had a cardioembolic stroke. On discharge, the
mean modiﬁed Rankin Scale was 2.02.0. Moreover, 862 of
1003 of the population were prescribed antiplatelets only,
85 of 1003 used an anticoagulant only (50/85 warfarin,
35/85 non–vitamin K antagonist oral anticoagulant), and
19 of 1003 were on an antiplatelet and an anticoagulant.
Thirty-seven patients were not on an antithrombotic agent at
discharge.
A high microbleed burden (≥5) was independently associ-
ated with premorbid antiplatelet use (multivariate adjusted
odds ratio: 2.01; 95% conﬁdence interval [CI], 1.17–3.47;
P=0.012) and anticoagulant use (adjusted odds ratio: 4.47;
95% CI, 1.17–17.10; P=0.029) as well as a severe burden of
subcortical and periventricular WMH and BG perivascular
spaces (all P<0.0001; Table 2). There was a trend that a high
microbleed burden was also associated with a history of
hypertension (P=0.057). A comparison of clinical and neu-
roimaging characteristics of patients with microbleeds of
different locations is shown in Table 3. Compared with
patients with no, strictly deep, or strictly lobar microbleeds,
patients with mixed microbleeds were older (P=0.001), had a
higher prevalence of hypertension (P=0.005), renal impair-
ment (P=0.002), and overall more severe burden of SVD
(Table 3). Multivariate analysis revealed that hypertension
(adjusted odds ratio: 1.58; 95% CI, 1.05–2.39; P=0.029);
premorbid anticoagulant use (adjusted odds ratio: 4.33; 95%
CI, 1.42–13.25; P=0.010); and severe burden of subcortical,
periventricular WMH, and BG perivascular spaces (all
P=0.035
R
is
k 
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)
0 1 2-4 ≥5 Microbleeds
Time (years)
P<0.0001
R
is
k 
(%
)
A
B
Figure 1. Risk of recurrent ischemic stroke (A) and intracere-
bral hemorrhage (B) in ischemic stroke patients with increasing
cerebral microbleed burden. Statistical signiﬁcance of differences
in risk determined by log rank test.
Table 6. Cox Regression Analyses of Risk of Recurrent Ischemic Stroke and Intracerebral Hemorrhage With Presence vs Absence
of Microbleeds, Stratiﬁed by Antithrombotic Use
Unadjusted SHR
(95% CI) P Value
Age and Sex Adjusted
SHR (95% CI) P Value
Multivariate* Adjusted
SHR (95% CI) P Value
Recurrent ischemic stroke
All patients (n=1003) 1.52 (1.01–2.29) 0.044 1.40 (0.93–2.11) 0.11 1.49 (0.97–2.27) 0.067
Antiplatelet users† (n=862) 1.47 (0.94–2.31) 0.092 1.33 (0.85–2.10) 0.21 1.41 (0.88–2.26) 0.15
Warfarin users‡ (n=50) 2.74 (0.51–14.51) 0.24    
NOAC users‡ (n=35) 2.64 (0.46–15.14) 0.28    
Intracerebral hemorrhage
All patients (n=1003) 3.71 (1.35–10.21) 0.011 3.46 (1.23–9.78) 0.019 3.52 (1.26–9.85) 0.016
Antiplatelet users† (n=862) 5.28 (1.51–18.51) 0.009 4.84 (1.37–17.06) 0.014 4.64 (1.29–16.70) 0.019
Warfarin users‡ (n=50) 2.69 (0.24–30.36) 0.42   
CI indicates conﬁdence interval; NOAC, non–vitamin K antagonist oral anticoagulant; SHR, subdistribution hazard ratio.
*Hypertension, hyperlipidemia, diabetes mellitus, smoking history, and atrial ﬁbrillation.
†Anticoagulant users excluded.
‡Antiplatelet users excluded; only univariate SHRs provided with <10 recurrent events.
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P<0.0001) were independent predictors of microbleeds of
mixed location (Table 4).
During a mean follow-up of 3720 years (3126 patient-
years), 113 patients developed a recurrent stroke, of which 93
(82%) had ischemic strokes (Table 1). In total, 130 patients
died during follow-up (46% vascular deaths). The absolute
event rates and 5-year absolute risks of recurrent ischemic
stroke and ICH after ischemic stroke of patients with different
burden and locations of microbleeds is shown in Table 5 and
Figure 1. In the 20 patients with ICH, 15 had underlying
microbleeds, of which 11 had ≥5 and 14 were of mixed
location. In 11 of 15 of patients, the ICH location corresponded
to a prior microbleed detected on MRI. When patients were
stratiﬁed by presence versus absence of microbleeds, patients
who had microbleeds were at increased risk of recurrent
ischemic stroke on univariate analysis (SHR: 1.52; 95% CI,
1.01–2.29; P=0.044), but this did not reach statistical
signiﬁcance on multivariate analysis (P=0.067; Table 6).
Similar ﬁndings were noted when microbleeds were stratiﬁed
according to burden (P=0.051) (Table 7). In contrast, presence
of microbleeds (multivariate adjusted SHR: 3.52; 95% CI, 1.26–
9.85; P=0.016) and burden of microbleeds (burden versus no
microbleeds: 1 microbleed: SHR: 0.59 [95% CI, 0.07–4.99]; 2–
4 microbleeds: SHR: 2.14 [95% CI, 0.51–9.02]; ≥5 microb-
leeds: SHR: 9.30 [95% CI, 2.98–29.03]; Ptrend<0.0001) were
both independently associated with subsequent risk of ICH
compared with patients with no microbleeds (Tables 6 and 7).
Microbleeds were not associated with all-cause mortality or
vascular death (Tables 8 and 9).
We stratiﬁed our results according to the use of
antithrombotic agents after diagnosis of ischemic stroke.
The absolute event rates and 5-year absolute risks of
recurrent ischemic stroke and ICH in 862 of 1003 antiplatelet
users (anticoagulant users excluded) by microbleed burden
and location are shown in Table 5 and Figure 2. Compared
with no microbleeds, antiplatelet users with microbleeds
were similarly at increased risk of ICH (multivariate adjusted
SHR: 4.64; 95% CI, 1.29–16.70; P=0.019) but not recurrent
ischemic stroke (P=0.15; Table 6). Similar ﬁndings
were noted when antiplatelet users were stratiﬁed by
microbleed burden and a signiﬁcant increase in risk of
ICH (burden versus no microbleeds: 1 microbleed: multi-
variate adjusted SHR: 0.91 [95% CI, 0.09–8.72]; 2–4
microbleeds: multivariate adjusted SHR: 2.22 [95% CI,
0.38–12.98]; ≥5 microbleeds: multivariate adjusted SHR:
12.98 [95% CI, 3.27–51.58]; Ptrend=0.001), but not recurrent
ischemic stroke (Ptrend=0.11) was noted with increasing
microbleed burden (Table 7). In antiplatelet users, an
increasing burden of microbleeds was associated with all-
cause mortality (Ptrend=0.046) on multivariate analysis, but
this was not signiﬁcant when only vascular deaths were
studied (Ptrend=0.12; Tables 8 and 9). T
ab
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Of the 50 patients on warfarin (antiplatelet users
excluded), 6 developed recurrent ischemic stroke and 3
developed ICH during a mean 44.321 months of follow-up
(see Table 5). Warfarin users with microbleeds were not at
increased risk of recurrent ischemic stroke (univariate SHR:
2.74; 95% CI, 0.51–14.51; P=0.24) or ICH (univariate SHR:
Table 8. Cox Regression Analyses of All Death and Vascular Death With Presence of Microbleeds vs No Microbleeds, Stratiﬁed by
Antithrombotic Use
Unadjusted HR
(95% CI) P Value
Age- and Sex-Adjusted
HR (95% CI) P Value
Multivariate*
Adjusted HR (95% CI) P Value
All death
All patients (n=1003) 1.34 (0.95–1.90) 0.093 1.12 (0.80–1.59) 0.51 1.16 (0.82–1.64) 0.40
Antiplatelet users† (n=862) 1.56 (1.04–2.33) 0.031 1.28 (0.85–1.91) 0.24 1.29 (0.86–1.94) 0.23
Warfarin users‡ (n=50) 1.45 (0.42–5.03) 0.56 1.66 (0.45–6.09) 0.45 0.59 (0.10–3.73) 0.58
Unadjusted SHR
(95% CI) P Value
Age and Sex Adjusted
SHR (95% CI) P Value
Multivariate*
Adjusted SHR (95% CI) P Value
Vascular death
All patients (n=1003) 1.43 (0.86–2.37) 0.16 1.24 (0.74–2.07) 0.42 1.27 (0.76–2.14) 0.36
Antiplatelet users† (n=862) 1.84 (1.00–3.40) 0.050 1.56 (0.84–2.90) 0.16 1.57 (0.83–2.97) 0.16
Warfarin users‡ (n=50) 2.34 (0.57–9.54) 0.24    
CI indicates conﬁdence interval; HR, hazard ratio; SHR, subdistribution hazard ratio.
*Hypertension, hyperlipidemia, diabetes mellitus, smoking history, and atrial ﬁbrillation.
†Anticoagulant users excluded.
‡Antiplatelet users excluded; only univariate SHRs provided for vascular death with <10 events.
Table 9. Cox Regression Analyses of All Death and Vascular Death With Increasing Burden of Microbleeds vs No Microbleeds,
Stratiﬁed by Antithrombotic Use
No. of Microbleeds, HR (95% CI)
Unadjusted Adjusted for Age, Sex, and Vascular Risk Factors*
1 2–4 ≥5 Ptrend 1 2–4 ≥5 Ptrend
All death
All patients
(n=1003)
0.97 (0.59–1.59) 1.48 (0.92–2.39) 1.81 (1.13–2.92) 0.009 0.89 (0.54–1.46) 1.19 (0.73–1.93) 1.55 (0.96–2.50) 0.091
Antiplatelet
users†
(n=862)
1.08 (0.61–1.91) 1.73 (1.00–3.00) 2.18 (1.27–3.74) 0.002 0.90 (0.51–1.61) 1.56 (0.89–2.72) 1.63 (0.93–2.86) 0.046
Warfarin
users‡
(n=50)
0.85 (0.16–4.37) 1.63 (0.19–14.03) 4.35 (0.84–22.57) 0.14 0.36 (0.04–3.54) 0.18 (0.01–3.98) 2.23 (0.24–20.99) 0.77
No. of Microbleeds, SHR (95% CI)
Unadjusted Adjusted for Age, Sex, and Vascular Risk Factors*
Vascular death
All patients
(n=1003)
1.16 (0.58–2.31) 1.71 (0.87–3.37) 1.54 (0.72–3.28) 0.11 1.08 (0.53–2.18) 1.41 (0.69–2.88) 1.40 (0.64–3.04) 0.27
Antiplatelet
users†
(n=862)
1.37 (0.60–3.16) 2.41 (1.11–5.29) 1.95 (0.80–4.72) 0.028 1.22 (0.52–2.87) 2.06 (0.90–4.69) 1.55 (0.62–3.87) 0.12
Warfarin
users‡
(n=50)
1.37 (0.25–7.40) 2.58 (0.28–23.82) 6.84 (0.96–49.02) 0.068   
CI indicates conﬁdence interval; HR, hazard ratio; SHR, subdistribution hazard ratio.
*Hypertension, hyperlipidemia, diabetes mellitus, smoking history, and atrial ﬁbrillation.
†Anticoagulant users excluded.
‡Antiplatelet users excluded.
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2.69; 95% CI, 0.24–30.36; P=0.42; Table 6). Thirty-ﬁve
patients were on non–vitamin K antagonist oral anticoagu-
lants, 5 of whom developed recurrent ischemic stroke (2/5
with no microbleeds, 1/5 with 1 microbleed, and 2/5 with 2–
4 microbleeds; 1/5 had microbleeds of mixed location);
however, none of the 13 patients with microbleeds (3/13 with
1 microbleed, 6/13 with 2–4 microbleeds, and 4/13 with ≥5
microbleeds; 8/13 had microbleeds of mixed location)
developed an ICH with mean 26.413.5 months of follow-up.
In a multivariate analysis including age, sex, vascular risk
factors, postevent antithrombotic use, microbleed burden,
microbleed location, and other neuroimaging markers of SVD,
only having ≥5 microbleeds (SHR: 6.08; 95% CI, 1.11–33.21;
P=0.037) was identiﬁed as an independent predictor of ICH
(Table 10). In contrast, age, hyperlipidemia, smoking history,
and atrial ﬁbrillation (all P<0.05) were identiﬁed as indepen-
dent predictors of recurrent ischemic stroke, but neuroimag-
ing markers of SVD were not (Table 11).
Discussion
Our study includes one of the largest cohorts for the long-
term prognostic implications of cerebral microbleeds in
patients with ischemic stroke by adding 3100 patient-years
of follow-up data to 9500 patient-years included in a recent
systematic review of 15 smaller studies.4 Overall, 45% of
ischemic stroke patients in our cohort were noted to have
microbleeds. This was similar to the prevalence noted in other
Asian cohorts (23–50%) but higher than those observed in an
unpublished Western cohort of ischemic stroke patients
(20%).4 However, direct comparisons of microbleed preva-
lence among ischemic stroke patients from the East and the
West are limited because most reported Western cohorts also
consisted of transient ischemic attack patients, for whom the
prevalence of microbleeds is known to be lower.1,4
The majority of patients with microbleeds in our cohort
(42%) had microbleeds of mixed location, whereas 36% of
patients had strictly lobar microbleeds and 16% had strictly
deep microbleeds. Consistent with recent meta-analysis,4
microbleeds of mixed location are known to be more common
among Asian compared with white cohorts (8–40% versus
5–15%), likely because of underlying differences in risk factor
proﬁle and greater prevalence of hypertension.4,7 Microbleeds
of mixed location are, by deﬁnition, multiple; are often
associated with a high microbleed burden (109/187 [58%]
patients with microbleeds of mixed location in our cohort
had ≥5); and are likely to represent a severe form of
microangiopathy, due to either severe hypertension or a
combination of hypertension and cerebral amyloid angiopa-
thy. Our results are in line with this ﬁnding because patients
who had mixed microbleeds or ≥5 microbleeds had the
highest 5-year absolute risk of an ICH, at 10.8% and 12.3%
respectively.
Our hazard ratios for prediction of recurrent stroke based on
microbleed burden were generally similar with the pooled
estimates from the previousmeta-analysis.4 However, although
this meta-analysis was able to demonstrate that patients with
the presence or an increasing burden of microbleeds were at
higher risk of recurrent ischemic stroke,4 these analyses did not
reach statistical signiﬁcance in our cohort after adjusting for
age, sex, and other vascular risk factors. Stratifying our results
by antithrombotic use and including only patients who were on
antiplatelet agents on discharge did not alter our ﬁndings.
Interestingly, in a multivariate regression model accounting for
all vascular risk factors, microbleed burden, microbleed
location, and other neuroimaging markers of SVD, only
traditional vascular risk factors such as age, hyperlipidemia,
smoking history, and atrial ﬁbrillation remained signiﬁcant
independent predictors of recurrent ischemic stroke risk.
Nevertheless, our ﬁndings on the prognostic implications of
microbleed burden support recent expert recommendations
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Figure 2. Risk of recurrent ischemic stroke (A) and intracere-
bral hemorrhage (B) in ischemic stroke patients on antiplatelet
agents with increasing cerebral microbleed burden. Statistical
signiﬁcance of differences in risk determined by log rank test.
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suggesting that in ischemic stroke patients with <5 microb-
leeds, antiplatelet agents should not be contraindicated, as the
absolute risk of recurrent ischemic stroke in this group of
patients is likely to signiﬁcantly outweigh the risk of ICH.18
These expert recommendations also suggest that in patients
with ≥5 microbleeds, the beneﬁts and potential risks of
antiplatelet agents would need to be carefully balanced
because the long-term absolute risks of ICH are likely to be
similar to the absolute risks of recurrent ischemic stroke, and
our results are concordant with these recommendations.18
Although thisMRI-based cohort is currently one of the largest
used to investigate the long-term prognostic implications of
microbleeds in patients with ischemic stroke, our study is not
without limitations. Our cohort is limited to ischemic stroke
patients who were referred for MRI. Themajority of patients had
strokes that were of mild-moderate severity; patients who were
severely debilitated or deemed unﬁt for transfer did not receive
an MRI scan. The majority of patients referred for MRI were also
of small vessel or large artery atherosclerosis subtypes. This
would have resulted in selection bias in our cohort of patients
and may have limited the generalizability of our ﬁndings. In
addition, the median delay from admission to scan was 4 days,
and only a small proportion of patients (37/1003) received
intravenous thrombolysis. Whether underlying microbleed bur-
den is associated with an increased risk of hemorrhagic
transformation after thrombolysis could not be determined.
Moreover, our ﬁndings that suggest patients with microbleeds
of mixed location are at high risk of developing ICH are
comparable with those from a recent meta-analysis4; however,
further individual patient data meta-analyses, such as those
from theMicrobleeds International Collaborative Network19 and
the META-MICROBLEEDS Consortium,20 would be able to
provide more deﬁnitive recommendations as to the implications
of microbleed burden versus microbleed location in the
prediction of subsequent stroke risk and the possible underlying
ethnic interactions. Furthermore, although we stratiﬁed our
analyses by antithrombotic use, we do not have exact data for all
patients’ medications throughout the entire follow-up period
and thus are uncertain about the exact rates of compliance.
Finally, although we attempted to study the prognostic impli-
cations of microbleeds in patients on warfarin or non–vitamin K
antagonist oral anticoagulants at discharge, we were limited in
power, with only 85 patients taking anticoagulants without
antiplatelets. Clinical trials such as CROMIS-2 (Clinical
Table 10. Clinical and Neuroimaging Predictors of Intracerebral Hemorrhage
Univariate SHR (95% CI) P Value Multivariate SHR* (95% CI) P Value
Age 1.02 (0.98–1.07) 0.29 
Male sex 1.52 (0.58–3.94) 0.39 
Hypertension 2.92 (0.86–9.94) 0.087 
Diabetes mellitus 0.64 (0.22–1.93) 0.43 
Hyperlipidemia 0.97 (0.35–2.67) 0.96 
Ever smoker 0.77 (0.28–2.12) 0.62 
Atrial fibrillation 1.73 (0.58–5.16) 0.32 
GFR <60 mL/min/1.73 m2 1.00 (1.00–1.00) 0.42 
Single antiplatelet use 0.59 (0.23–1.50) 0.27 
Dual antiplatelet use 1.30 (0.38–4.46) 0.67 
Warfarin use 2.41 (0.73–7.93) 0.15 
≥5 microbleeds 9.72 (4.05–23.35) <0.0001 6.08 (1.11–33.21) 0.037
Strictly deep microbleeds 5.85 (2.40–14.30) <0.0001 
Strictly lobar microbleeds 4.56 (1.76–11.84) 0.002 
Strictly infratentorial microbleeds 3.61 (1.48–8.80) 0.005 
Periventricular WMH burden 1.80 (1.18–2.75) 0.007 
Subcortical WMH burden 1.50 (0.96–2.37) 0.077 
Basal ganglia PVS burden 1.96 (1.02–3.76) 0.042 
Centrum semiovale PVS burden 0.93 (0.47–1.81) 0.82 
Lacunes 0.84 (0.62–1.15) 0.28 
CI indicates conﬁdence interval; GFR, glomerular ﬁltration rate; PVS, periventricular space; SHR, subdistribution hazard ratio; WMH, white matter hyperintensity.
*All variables in univariate analysis placed into multivariate analysis model.
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Relevance of Microbleeds in Stroke Study) and HERO (Intrac-
erebral Hemorrhage Due to Oral Anticoagulants: Prediction of
the Risk by Magnetic Resonance) are currently under way and
will provide important insights regarding the use of anticoag-
ulants in patients with microbleeds.21
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